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The treatment and management of ocular allergy (OA) remains a major concern for 
different specialties, including allergists, ophthalmologists, primary care physicians, 
rhinologists, pediatricians, dermatologists, clinical immunologists and pharmacists. We 
performed a systematic review of all relevant publications in Medline, SCOPUS and 
WebScience including systematic reviews and meta-analysis. Publications were considered 
relevant if they addressed treatments, or management strategies of OA. A further wider 
systematic literature search was performed if no evidence or good quality evidence was 
found. There are effective drugs for the treatment of OA, however there is a lack an optimal 
treatment for the perennial and severe forms. Topical antihistamines, mast cell stabilizers or 
double action drugs are the first choice of treatment. All of them are effective in reducing 
signs and symptoms of OA. The safety and optimal dosing regimen of the most effective 
topical anti-inflammatory drugs, corticosteroids, is still a major concern. Topical calcineurine 
inhibitors may be used in steroid-dependent/resistant cases of severe allergic 
keratoconjunctivitis. Allergen specific immunotherapy may be considered in cases of failure 
of first line treatments or to modify the natural course of OA disease. Based on the current 
wealth of publications and on the collective experience, recommendations on management 








Ocular allergy (OA) represents a collection of ocular hypersensitivity disorders affecting the 
eyelid, conjunctiva and cornea. OA includes seasonal and perennial allergic conjunctivitis 
(SAC and PAC), vernal and atopic keratoconjunctivitis (VKC and AKC) and contact 
blepharoconjunctivitis (CBC) (1). These clinical subtypes may be diagnosed and managed by 
ophthalmologists, allergists, pediatricians and rhinologists, with or without experience in 
managing allergies, considering clinical history and signs and symptoms, aided by in vivo and 
in vitro tests (1-3). Although several studies suggest a high co-morbidity of conjunctivitis and 
rhinitis, conjunctival symptoms are often perceived by clinicians as a minor problem and 
sub-optimally treated. A recent survey revealed that daily treatment of OA has little 
concordance with current recommendations(4). Topical ocular decongestants and 
corticosteroids were used in the majority of cases. This was independent of the specific 
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are the first line therapy in most published recommendations, were used less frequently (4). 
The incorrect management of OA may increase the risk of local and systemic treatment-
related side effects (4). This systematic review (SR) intends to provide a comprehensive 
overview of the currently available treatments for OA and of ocular comorbidities and/or 
complication, and suggest recommendations for their management using best available 




General Search Strategy 
The literature search was based on the systematic literature search in Medline, SCOPUS and 
WebScience. First, we performed a SR of all SR and meta-analyses that addressed OA 
treatments, according to the search query. For each subtype of OA or treatment, if good 
quality SR or systematic analysis of randomized controlled trials (RCTs) were found, no 
further systematic search was performed. If no evidence or poor quality of evidence was 
found, a further systematic search was performed. The included literature was selected with 
respect to their hierarchy in the ‘evidence pyramid’.  
 
Eligibility Criteria  
We included SR of observational and interventional studies regarding treatment of OA (SAC, 
PAC, VKC, AKC and CBC). The following treatments were included: anti-histamines, mast cell 
stabilizers, dual-acting agents (topical mast cell stabilizers and anti-histamines), non-
steroidal anti-inflammatory drugs (prostaglandin and leukotriene inhibitors), steroids, 
calcineurin inhibitors, allergen-specific immunotherapy and biologics. A SR was defined as a 
review of the literature with a predetermined and transparent search strategy, where the 
search strategy and inclusion and exclusion criteria were explicitly described and included 
guidelines or position papers containing information regarding quality of evidence.  Our 
systematic literature search included non-pharmacological interventions including surgery, 
psychological, lid hygiene and lubricants.  
 
Specific search strategy, selection of the study, and assessment of the quality of the 




The flowchart of the selection strategy is shown in Figure 1.  
 
1. Overview of the available pharmacological classes of anti-allergic drugs 
There is a wide range of treatment options for OA, some of which are off-label. Currently 
available topical drugs for OA can be classified into different pharmacological classes based 
on their mechanism of action (Table 1): anti-histamines, mast cell stabilizers, dual-acting 
agents (topical mast cell stabilizers and anti-histamines), alpha-adrenergic agonists 
(vasoconstrictors), non-steroidal anti-inflammatory drugs (prostaglandin inhibitors), 
corticosteroids, and calcineurin inhibitors. Immunomodulatory treatments for OA include 
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1.1 Topical anti-histamines, mast cell stabilizers and dual-acting agents  
Three SR addressed the use of topical anti-histamines, topical mast cell stabilizers or topical 
dual-acting agents for the treatment of SAC and PAC (Table 2): one included 23 RCTs (5), the 
second 30 RCTs (6) in a head-to-head study, and the third 41 RCTs (7). All the 3 reviews 
concluded that these drugs were effective in reducing ocular symptoms vs. placebo (7). 
Direct comparisons of different antihistamines and mast cell stabilizers showed insufficient 
evidence to recommend one drug over another (6) even though the peer-reviewed 
literature suggested that olopatadine may be clinically superior to the other anti-allergic 
molecules (8), and alcaftadine may be superior to olopatadine in reducing ocular itch (5). A 
fourth SR (9) comparing olopatadine with other topical anti-histamines (epinastine, 
ketotifen, alcaftadine), showed a significant benefit from the use of alcaftadine in reducing 
symptoms scores when compared to the others drugs. Alcaftadine is only currently 
approved and available in the US. Since the publication of the last SR, a further clinical trial 
has been published demonstrating efficacy of epinastine in controlling symptoms of birch 
pollen allergic patients (10). 
Overall, topical antihistamines and mast cell stabilizers appear to be safe and well tolerated 
(6, 11). The most frequently reported side effects from the use of these agents were burning 
and stinging sensation, blurred vision and unacceptable aftertaste (5, 6). Data on their long-
term efficacy and safety is still lacking. To minimize possible toxic effects of preservative 
compounds on the ocular surface, single dose preservative-free eye drops should be used 
whenever possible. 
A SR of 20 RCT evaluated the efficacy of topical anti-histamines and mast cell stabilizers for 
the treatment of VKC showing an improvement of ocular symptoms score with use of all 
these drugs (12). The pooled data was unable to recommend use of one agent over the 
other. A RCT published after this SR showed benefit with improved inflammatory 
biomarkers and total symptom score using preservative free N-acetyl-aspartyl-glutamic acid 
(NAAGA) compared to levocabastine (13). 
The treatment of AKC with anti-histamines and mast cell stabilizers has only been reported 
in a few case reports and case series (14). 
 
Recommendations 
 All topical drugs are effective in reducing signs and symptoms ⨁⨁⨁⨁↑↑  
 Topical antihistamines and dual acting drugs may have lead to a quicker onset 
symptom relief when compared to mast cell stabilizers ⨁◯◯◯↑?  
 Dual acting agents with combined mast cell stabilizer and antihistaminic function 
provide better symptom control ⨁◯◯◯↑?  
 Mast cell stabilizers such as chromones require multiple daily doses and have a 
delayed onset of action, hence are less preferable ⨁◯◯◯↑?  
 SAC and PAC can be managed using the same drugs ⨁⨁⨁⨁ ↑↑  
 The duration of treatment is longer in PAC compared to SAC ⨁◯◯◯↑?  
 Topical antihistamines and mast cell stabilizers can be used in VKC ⨁⨁◯◯↑ and 
AKC ⨁◯◯◯↑? 
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1.2 Topical alpha-adrenergic agonists (vasoconstrictors) 
Topical decongestants are frequently used as first-line treatment due to their availability 
over the counter (4). They merely alleviate hyperemia, having little to no relief from itch and 
a short duration of action (7). In a recent randomized controlled trial comparing several 
treatment options, the use of naphazoline/antazoline was associated with lower tolerability 
profile of all treatment. They may cause side effects such as rebound redness, chronic 
follicular conjunctivitis and tachyphylaxis. In older formulations ocular decongestants are 
paired with topical 1st generation antihistamines, such as pheniramine and antazoline, to 
relieve both itching and redness. 
  
Recommendations  
 Vasoconstrictors alleviate only hyperemia ⨁◯◯◯ ↑? 
 They should be used with caution and for a short period of 5-7 days because of side 
effects and tachyphylaxis (TF expert opinion)↑↑  
 
1.3 Non-steroidal anti-inflammatory drugs NSAID (topical prostaglandin and oral 
leukotriene inhibitors)  
One SR (15) based on 8 RCTs, concluded that topical NSAIDS are more effective than 
placebo in reducing ocular itching and redness. Use of varied outcome parameters did not 
permit a comparison (15, 16) (Table 3). NSAIDs are rarely used due to their local side effects, 
such as burning/stinging after application. 
The oral leukotriene inhibitor montelukast has shown to be useful in the treatment of ocular 
symptoms in SAC and PAC, but less effective than oral anti-histamines (17). 
 
Recommendations from the TF group 
 NSAIDs are effective for their short-term use but do not target specific inflammatory 
mechanisms ⨁◯◯◯↓?  
 In adult SAC patients, leukotriene inhibitors are less efficacious than oral 
antihistamines ⨁◯◯◯↑? 
 
1.4 Systemic antihistamines  
Oral anti-histamines are frequently used in case of allergic co-morbidities such as rhinitis 
and are used in almost one third of the patients with ocular symptoms(4). Drugs such as 
loratadine, desloratadine(18), fexofenadine(19) are highly effective for the treatment of 
allergic rhinoconjunctivitis (ARC) (Table 4). Most of the SRs have addressed total symptoms 
scores (18, 19), without evaluating impact on specific ocular symptoms. Itching and watery 
eye symptoms significantly improved after rupatadine treatment compared to placebo(20).  
While the drowsiness so commonly noted with the older 1st generation systemic 
antihistamines has improved in the newer second-generation anti-histamines, some of the 
new molecules still inhibit muscarinic receptors, leading to mucosal dryness(21, 22). 
Moreover, patients with dry eye have reduced barrier function at the mucosal interface 
against environmental allergens and pollutants and possibly a lower threshold for allergen 
response. Some oral antihistamines may exacerbate OA by lowering the barrier defense 
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Recommendations 
 Systemic anti-histamines should be used in case of comorbidities that require it use 
⨁◯◯◯↑? 
 Some systemic anti-histamines may induce drying effects, particularly relevant at the 
ocular surface barrier ⨁◯◯◯↑? 
 
1.4 Corticosteroids   
Should not be the first choice of therapy for OA. In clinical practice, they are the most 
effective anti-inflammatory agents in active OA. Because of potential adverse effects 
(increased intraocular pressure, with a potential evolution towards glaucoma, cataract 
formation, bacterial, viral and fungal super-infections), their use must be monitored by an 
ophthalmologist (especially in prolonged treatments). A SR (Table 5) on the use of a 
loteprednol eye drops for treating SAC (4 RCTs) and VKC (1 RCT) reached a high level of 
confidence using AMSTAR2 score (23), supporting the efficacy of this treatment. 
Loteprednol 0.5% and 0.2% were considered effective in treating signs and symptoms of 
SAC, but should be used with caution due to the higher incidence of intraocular pressure 
(IOP) elevation (pooled odds ratio = 3.03) compared with placebo and olopatadine (23). A 
second review demonstrated significantly lower rates of IOP elevation (>/=10 mm Hg) when 
compared to topical prednisolone 1% or dexamethasone 0.1%, suggesting a favorable IOP-
safety profile for loteprednol with both short-term and long-term use. However, this review 
received a critically low AMSTAR score (24). 
A wide variety of corticosteroid eye drops of different potencies are available across the 
world (Table 1) (1). There are no studies directly comparing formulation, strength or 
regimen of any specific corticosteroid over another for the treatment of OA. There are two 
main regimens used in OA: 1) pulsed therapy of 3-4 drops per day for 3 to 5 days; 2) 
prolonged treatment of 1 to 3 weeks, tapered slowly over several days. Pulsed therapy is 
the favored treatment of acute exacerbations of VKC and AKC especially when the cornea is 
involved. The potency and treatment duration of the topical corticosteroid should be 
chosen clinically based on the severity of ocular inflammation and corneal involvement. 
 
The beneficial effect of intranasal corticosteroids (INCs) on ocular symptoms has been 
demonstrated in several studies suggesting that their reduction is mediated via the ocular-
nasal reflex inhibition. The variability of the effect depends on the affinity of the drug to its 
glucocorticoid receptor(25). Four SR evaluated the use of INCs for the treatment of ocular 
symptoms associated with allergic rhinitis(26, 27) (Table 5) showing that INCs are well-
tolerated and effective in reducing the total ocular symptom score (TOSS), even though the 
outcome measures were not designed to focus specifically on ocular symptoms. It is noted 
that oral/topical antihistamines are not superior to INCs in reducing TOSS (28, 29). However, 
despite large patient cohorts, all SR had a low or critically low confidence rating of results 
according to AMSTAR2. A recent metanalysis of 3 RCTs noted benefit of a topical nasal 
combination, fluticasone proprionate and azelastine on TOSS in patients with seasonal ARC 
(30). 
There are no studies specifically comparing INCs against each other for the treatment of 
ocular symptoms. Although data is scarce, there is no evidence that INCs used for prolonged 
periods of several months increase the risk of cataract formation, intraocular hypertension 
and glaucoma, since they have little or no systemic absorption (fluticasone and 
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The use of corticosteroids as dermatologic applications in OA is reserved for AKC and CBC 
(1). Lowest appropriate potency corticosteroids, such as hydrocortisone or budesonide on 
the eyelid skin, are recommended for the treatment of severe acute eyelid eczema.  
 
Supra-tarsal injections of dexamethasone sodium phosphate, triamcinolone acetonide or 
hydrocortisone sodium succinate, have been proposed to treat recalcitrant AKC and VKC 
cases (31), but should only be used by specialists with caution in severe patients 
unresponsive to other treatments. 
 
Systemic corticosteroids may be used as short course in selected severe hyper-acute 
exacerbations involving either eyelid skin or cornea especially in VKC and AKC. 
 
Recommendations 
 Topical corticosteroids eye drops should be used with caution under 
ophthalmologist’s monitoring and preferably for shorter duration due to the high risk of 
local and potential blinding side effects ⨁◯◯◯↑↑ 
 For the treatment of SAC and PAC topical corticosteroids are rarely needed 
⨁◯◯◯↓↓ 
 Corticosteroid eye drops can be used preferably as short, pulsed therapy in acute 
exacerbations of OA, especially in VKC and AKC or when the cornea is involved under 
ophthalmologist supervision (TF expert opinion)↑↑ 
 INCs are effective and well-tolerated in the treatment of ocular symptoms associated 
with ARC ⨁◯◯◯ ↑? 
 INCs should not be used if only ocular signs and symptoms are present (TF expert 
opinion) ↓↓ 
 Topical skin corticosteroid applications should be used in the acute phase of eyelid 
eczema, with a preference for low potency corticosteroids (TF expert opinion) ↑? 
 
1.5 Calcineurin inhibitors  
Topical calcineurin inhibitors are the most frequently used treatments as steroid-sparing 
agents in steroid dependent cases of VKC and AKC. Two SR evaluated the use of topical 
cyclosporine (CsA) in VKC and AKC (32, 33) (Table 5). The first one showed that topical CsA is 
effective in alleviating the signs and symptoms of VKC and AKC, reducing the dependency on 
topical steroid eye drops while maintaining similar safety profile as of placebo. The second 
SR, highlighted the relative scarcity of RCTs assessing the efficacy of topical CsA in AKC, and 
suggested that CsA provides clinical and symptomatic improvement and may help in 
reducing topical steroid use in patients with steroid-dependent or non steroid-responsive 
AKC (33).  
Compounded formulations of CsA are prepared in many countries by hospital and retail 
pharmacies with differing excipients, processes, and quality. Drug concentrations range 
from 0.05% to 2% and posology from 1 to 6 instillations daily. 
CsA 0.1% cationic emulsion (CE) is commercially available for the treatment of severe dry 
eye disease(34). The same formulation has obtained in 2018 the marketing authorization by 
EMA for the treatment of severe VKC. Severe VKC patients treated with this formulation 
achieved significant improvements in signs, symptoms and QoL compared with patients who 
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Tacrolimus 0.03%-0.1% eye drops or ointments have been proposed for the treatment of 
severe, refractory cases of AKC and VKC. A commercial eye drop preparation is available 
only in Asia with the indication of severe AKC and VKC. One review, with a critically low 
quality of evidence score, highlighted the benefits of tacrolimus over placebo in 2 RCTs and 
4 case series (36) (Table 5). A RCT comparing the effect of tacrolimus 0.1% versus CsA 2% 
(37) showed that both drugs were effective in treating VKC without significant differences 
between the two. In a second RCT, CsA-resistant VKC patients (38), treated with tacrolimus 
0.1% showed a significant improvement in clinical scores over CsA 1%. A recent trial 
comparing the effect of 0.1% topical tacrolimus alone or in combination with topical 
corticosteroids in refractory allergic ocular diseases also showed a potential steroid-sparing 
effect (39). In addition, tacrolimus skin ointments 0.03% or 0.1% have been shown to be 
beneficial in the treatment of lid eczema in AKC patients (40-42). Tolerability of topical 
calcineurin inhibitors is a concern as burning sensation is frequently reported. Infections 
with molluscum contagiosum, papilloma virus and herpes are infrequent but are recognized 
risks. 
A systemic immunosuppressive treatment may be prescribed in most refractory cases of 
AKC threatening vision. Cyclosporine is the most frequently used drug (43). Tacrolimus and 
mycophenolate mofetil are alternative options. 
 
Recommendations   
 CsA eye drops are not recommended for SAC and PAC (TF expert opinion)↑↑ 
 CsA eye drops may be used as a steroid-sparing agent in steroid-dependent cases of 
VKC or AKC ⨁⨁◯◯ ↑↑ 
 Tacrolimus off label eye drops/ointment should be reserved for use in severe VKC 
and AKC cases refractory to CsA ⨁◯◯◯↑?  
 
1.6 Allergen-specific immunotherapy 
Since in most patients OA is associated with AR, criteria for allergen immunotherapy (AIT) 
should follow the recommendations given by the EAACI guidelines(44). AIT should be 
consider only when IgE-mediated allergy is evidenced and when all of following criteria are 
met: moderate-to-severe symptoms strongly suggestive of ARC, which interfere with usual 
daily activities or sleep despite regular and appropriate pharmacotherapy and/or avoidance 
strategies and evidencing of IgE sensitization (positive SPT and/or serum-specific IgE) to one 
or more clinically relevant allergens(44, 45). In addition, conjunctival allergen provocation 
test may be helpful in detection of the most relevant allergen before initiating and as a 
follow-up tool in assessing response of AIT(2). AIT should also be considered in less severe 
ARC to take advantage of the long-term benefit on AR and potential prevention of asthma 
(46). Seven of the 8 selected SR with high and moderate AMSTAR2 scores (Table 6), 
recommended the use of SLIT and SCIT for moderate improvement of ocular symptoms in 
the treatment of ARC (45, 47-52). In two recent RCT regarding house dust mite 
immunotherapy, an improvement was seen in ocular symptoms score (53, 54). Only one SR 
(Table 6) (28 RCT including 1619 children and adolescents with ARC) showed low evidence 
of the efficacy of SLIT and SCIT on ocular symptoms (55).   
Meta analysis showed evidence for AIT, with some heterogeneity, in both adults and 
children, with both SLIT and SCIT(52), drop and tablet formulations, in perennial and 
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formulations. Concerns were focused on standardization of allergen extracts and 
formulation of SLIT preparations. 
In cases of isolated allergic conjunctivitis, AIT may be considered. TOSS was evaluated as the 
primary outcome parameter in 36 studies (1725 SLIT and 1674 placebo) (51); TOSS was 
significantly reduced when compared with placebo, as well as individual ocular symptoms 
scores (redness, itchy and watery eyes). No significant reduction of ocular eye drops use was 
observed whereas the threshold dose for conjunctival immediate allergen sensitivity was 
increased. Two other SRs focusing on ocular symptoms (50) concluded that the evidence 
was of moderate strength in support of SLIT and low for SCIT for treating allergic 
conjunctivitis. No publication was found assessing impact of AIT in VKC and AKC. 
 
Recommendation 
 AIT may be considered in cases of failure of first line treatments or to modify the 
natural course of ocular allergic disease ⨁⨁◯◯↑? 
 AIT can only be considered only when IgE-mediated hypersensitivity is evidenced 
⨁⨁⨁⨁ ↑↑ 
 Before AIT is recommended, control of symptoms of allergic conjunctivitis and other 
systemic symptoms to assess suitability should be taken into account. ⨁⨁◯◯↑? 
 AIT is effective for the treatment of allergic conjunctivitis due to grass pollen 
(⨁⨁⨁⨁ ↑↑) and house dust mite (⨁⨁⨁◯↑?) 
 SLIT is effective in reducing total and individual ocular symptom score in subjects 
with allergic conjunctivitis ⨁⨁⨁⨁ ↑? 
 There are no studies on AIT in VKC and AKC patients. In these forms AIT requires 
case-to-case assessment by experts (TF expert opinion)↑? 
 
1.7 Biologicals  
Omalizumab, a systemic anti-IgE antibody approved for severe asthma, has been used in 
refractory VKC and AKC and reported in a few case reports/series (56). Control of the 
disease was partial or complete in most patients, but poor response was noted in some with 
very severe presentation (57).  
Dupilumab is a promising intervention in the management of atopic dermatitis and asthma, 
however, dupilumab-associated ocular inflammation leading to cicatricial ectropion has 




2. Non-pharmacological management  
Patients and caregivers should receive educative support regarding the anticipated duration 
and prognosis of the OA, and possible complications from suboptimal control (1). The first 
line of management is the identification of offending allergens and avoidance measures. 
Particularly during exacerbations in VKC, minimizing exposure to nonspecific triggering 
factors, such as sun, wind, and salty water, using measures such as sunglasses, hats with 
visors, and swimming goggles. Frequent hand, face, lid hygiene and eye washing should also 
be suggested. Cold compresses may provide decongestant effect. Tear substitutes aid in 
stabilization of the tear film providing a better mucosal barrier against allergens, acting as 
an eye-wash and diluting the concentration of mediators in the tear film in contact with the 
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should be avoided as they may cross-react with allergens (for example Artemisia 
vulgaris)(59) .  
Psychological support may be necessary in severe cases of VKC and AKC. The psychodynamic 
research on OA is currently poor. For patients with AKC and VKC, a collaborative approach 
between the family doctor, the medical specialist, the psychologist, and occupational 
therapists should be considered (60). There are reports of impact on QoL in different types 
of OA. There is a dearth of reported interventions of mitigation of psychological impact of 
the disease (3).  
 
 
3. Management in specific populations 
Pregnancy. Few reports are available in literature concerning the management of OA in 
pregnant or lactating women. Careful evaluation of allergic status and need of drug 
administration is warranted. Allergen avoidance and environmental measures are the first 
step, before mast cells stabilizers eye-drops can be used. Topical anti-histamines or double-
acting drugs can be safely tried.  As yet there is no evidence of severe adverse events with 
their use, although US-FDA has assigned many of them to the C category (use with caution if 
benefits outweigh risks). Short courses of topical corticosteroids if required, are cautiously 
permitted. Vasoconstrictors and decongestants are generally avoided during pregnancy. The 
use of systemic medications should be minimized if possible. Pregnant (especially in the first 
trimester) and lactating women can receive second-generation oral anti-histamine 
treatment (no teratogenic effects have been described), low concentrations of these drugs 
are secreted in breast milk (61, 62).  
Immunotherapy may be continued but not initiated in pregnancy (63).  
 
Children. Topical eye-drops used for adults are also approved in children over the age of 
three years, giving the advice to the subject to close the punctum with a finger to avoid 
systemic absorption. 
First-generation anti-histamines are not indicated because of the sedative effect; second-
generation anti-histamines display a good long-term safety profile in the pediatric 
population. The use of these drugs is not licensed in children under the age of six months 
(62). 
 
Elderly people. OA may persist into older age and can occasionally make its initial 
appearance in the elderly (64, 65). The complex process of the aging immune system, 
affects both the innate and the adaptive immunity, also on the ocular surface (66). 
However, structural changes of the eyelid, eyelid margin, lacrimal system, conjunctiva and 
the cornea more frequently induce a variety of ocular surface dysfunctions that can be 
broadly included under the umbrella of the dry eye disease (DED). Descriptions of OA in 
elderly are scarce. Therefore, OA treatment options in elderly patients may be limited by co-
morbidities and drug-interactions (64). Systemic and local corticosteroids in these patients 
should be limited to short-time administration because of their known side effects 
(diabetes, hypertension, osteoporosis, cataract and glaucoma). Topical and systemic 
decongestants, and systemic anti-histamines may cause dryness and should be avoided. In 
elderly patients, cumulative use of antihistamines and other anticholinergic drugs needs to 
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4. Treatments of ocular comorbidities and complications  
OA and DED are distinct clinical entities but some overlapping features suggest a complex 
interaction of mechanisms involving the immune, endocrine and nervous systems(68). For 
example, mucosal hyper-responsiveness to non-specific environmental stimuli has been 
described in both OA and DED. However, OA is mostly a disease of youth while DED is more 
common at an older age when signs and symptoms of allergy generally disappear. Artificial 
tears, routinely used for DED patients, may improve symptoms in all the clinical varieties of 
OA. Both OA and DED may show a favorable response to topical anti-inflammatory agents 
such as steroids and CsA(69). 
 
Corneal epithelial erosions, shield ulcers and plaques, frequently observed in AKC and VKC, 
occur as a result of mediators released from inflammatory cells and partially by the 
mechanical trauma from upper tarsal conjunctival giant papillae (GP) (70). Delayed epithelial 
healing may lead to secondary infections, corneal opacities and amblyopia.  
GP resection and cryotherapy are usually not necessary. GP excision with intraoperative 
application of 0.02% mitomycin-C may be helpful in preventing recurrent corneal 
complications in severe AKC and VKC cases.  
The treatment of corneal ulcer can be based on the Cameron clinical grading of shield ulcers 
(71, 72). Contact lenses and/or amniotic membrane grafts may be a useful treatment option 
in the management of refractory vernal ulcers (73). 
 
Allergic patients in childhood may develop keratoconus (74), a progressive, non-
inflammatory disorder of the cornea characterized by thinning and steepening in the central 
or paracentral cornea causing irregular astigmatism and subsequent decrease in visual 
acuity. Corneal cross-linking, consisting in the topical application of a 0.1% riboflavin 5-
phosphate solution to the de-epithelized corneal surface followed by exposure to UVA 
radiation, seems to be a safe and effective surgical option to arrest disease progression (75), 
which may be very aggressive in children(76).  
Visual rehabilitation in early and moderate stages consists of spectacles, contact lenses and 
intra-corneal ring implantation(77). 
Although the clinical outcome of corneal transplantation in keratoconus with and without 
VKC is comparable, post-operative complications are more common in VKC(78, 79). Atopy is 
a risk factor for complications after corneal grafting. 
 
Prolonged treatment with topical steroids should be avoided since glaucoma can occur in all 
age groups (24, 80). Withdrawal of steroids and addition of anti-glaucoma medications is 
effective in controlling IOP in the majority of patients(80). Glaucoma surgery is rarely 
necessary(81). 
 
Limbal stem cell deficiency (LSCD) is a rare complication of longstanding VKC and AKC, 
contributing to severe visual impairment(82). It is characterized by conjunctival epithelial 
ingrowth on the cornea, neovascularization, ocular surface inflammation, and/or recurrent 
corneal epithelial defects. Fibrovascular pannus resection with amniotic membrane 
transplantation(83) or allolimbal transplantation with systemic immunosuppression have 
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5. Final TF recommendations  
(Table 7, Figure 2) 
 
 
6. Conclusions and unmet needs 
There are effective drugs for the treatment of OA, however there is a lack an optimal 
treatment for the perennial and severe forms, especially for AKC and VKC. The safety and 
optimal dosing regimen of the most effective topical anti-inflammatory drugs, 
corticosteroids, is still a major concern but no specific randomized clinical trials have ever 
been performed because of the lack of marketing interest. There are no guidelines or 
consensus from scientific societies on how, when and duration of use of topical 
formulations of immunomodulators such as cyclosporine and tacrolimus.  
Pharmacological and immunological research has identified new possibilities to modifying 
the allergic immune response. Hopefully, this progress will be applied to the eye and 
eventually lead to complete control of moderate to severe forms of OA. However, just 
looking in the in www.clinicaltrials.gov for “ongoing clinical trials in allergic conjunctivitis”, it 
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Figure 1. Flowchart of the selection strategy of the systematic reviews potentially relevant 
for the purpose of the position paper. Of the 432 publications, 28 were selected and 
included (see Tables 2-6). 
 
Figure 2. Treatment of different forms and different severities of ocular allergies based on 
recommendations given by the TF. SAC= Seasonal allergic conjunctivitis; PAC= perennial 
allergic conjunctivitis; VKC= vernal keratoconjunctivitis; AKC= atopic keratoconjunctivitis; 
AH= antihistamines; CS= steroids; DA= dual actions; MCS= mast cell stabilizers; T= topical; 
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Tables 
Table 1. Topical Ocular Allergy Approved Medications 







- Relief of itching 
- Relief of signs and 
  symptoms  
- Short duration of action 
- Frequently not enough to treat alone the entire disease 





4x daily - Relief of signs 




- Long-term usage 
- Slow onset of action 
- Prophylactic dosing 
- Frequently not enough to treat alone the entire disease 
Dual-acting agents 









2x daily - Relief of itching 
- Relief of signs and symptoms 
- Bitter taste (azelastine) 
- No reported serious side effects 






2-4x daily - Rapid onset of action 
- Episodic itching and redness 
- Short duration of action 
- Tachyphylaxis 
- Mydriasis 
- Ocular irritation 
- Hypersensitivity 
- Systemic Hypertension 
- Potential for inappropriate patient use 
Corticosteroids 











As required - Treatment of allergic inflammation 
- Use in moderate to severe forms 
  
- Risk for long-term side effects 
- No mast cell stabilization 
- Potential for inappropriate patient use 
- Requires close monitoring 
Calcineurine inhibitors Cyclosporine A 
Tacrolimus 




-Off label in OA (tacrolimus approved for VKC only in Japan) 
-CsA 0.1% received marketing authorization by EMA in July 
2018 for severe VKC 
-Magistral/officinals preparations are different from center 
to center 
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Outcomes Main results Author`s conclusion Amstar 
score 
Topical anti-histamines 
Kam K et al 
2016(5) 











Olopatadine vs placebo 
Itch SMD -1.33[-1.43;-1.23]/Itch score -2.62[-3.25;-1.99] 
Hyperemia -0.92[-1.19;-0.65] / -1.92[-2.67;-1.17] 
Olopatadine vs Epinastine no significant differences 
Olopatadine vs Ketotifen no significant differences 
Olopatadine vs Alcaftadine SMD 0.30[0.28;0.50] 
Topical olopatadine is 
safe and effective, but 
alcaftadine appears to 
be superior 
High 


















watering eyes or 
photophobia) 
Mast cell stabilizers vs. placebo (8 RCT), not pooled, nedocromil 
sodium or sodium cromoglycate is more effective than placebo 
in improving ocular symptoms 
Azelastine vs. Placebo (9 RCT), not pooled, individuals studies 
improved symptoms 
Levocavastine vs. Placebo (5 RCT), not pooled, individual 
studies with improvement symptoms 
Olopatadine vs Ketotifen (4 RCT) MSD -0.32[-0.59;-0.06] for 
itching; MSD -0.06 [-0.35;0.22] for tearing 
Nedocromil vs. levobacastine (2 RCT), not pooled 
Azelastine vs levocabastine (2 RCT), not pooled 
Olopatadine vs control (2 RCT), not pooled, evidence from two 
small trials may improve symptoms 
Nedocromil vs azelastine (1 RCT), no difference 
Olopatadine vs nedocromil (1 RCT), olopatdine more effective 
Levocabastine vs antazoline and  tetryzoline, no difference 
Ketotifen vs placebo (1 RCT) more effective 
Ketotifen vs levocabastine (1RCT) Ketotifen is superior 
Levocabastine  and pemirolast vs levocabastine, combination is 
more effective 
Levocabastine vs mequitazine (1 RCT) equally effective 
Bepotastine vs placebo (1RCT), effective 
Bepotastine vs olopatadine (1RCT), insufficient 
 
All topical 
antihistamines and mast 
cell stabilizers reduce 
symptoms and signs of 
seasonal allergic 
conjunctivitis 
when compared with 
placebo in the short 
term are safe and well 
tolerated. 
Olopatadine may be 





2 RCT Allergic 
conjunctivitis 
(n=228) 
Alcaftadine 0.05 to 
0.25% vs placebo 
Ocular itching 
Ocular redness 
Improved ocular itching improvement, no improvement in 
ocular redness, not pooled 





et al 2005 (8) 










Not pooled No significant side effects; no ocular dryness or irritation with 
topical use. 
Reduces redness, itching and swelling. 
Comparison with ketorolac 0.5%, nedocromil, ketotifen, 
azelastine and epinastine- not pooled 
Olopatadine is clinically 
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Topical mast cell stabilizers 
Owen C et al, 
2004(7) 
40 RCT Seasonal allergic 
conjunctivitis 
(n=790) 
Topical mast cell 
stabilizers; topical 
anti-histamines 









Sodium cromoglycate vs placebo (8 RCT) OR =17[4;78] to 
benefit from treatment 
Nedocromil sodium vs placebo (5 RCT) OR =1.8[1.3;2.6] 
Lodoxamide tromethamine vs placebo (1 RCT) 
Topical anti-histamines vs placebo (9 RCT; 6 lebocabastine; 1 
azelastine; 1 emedastine; 1 antazoline) not pooled 
Topical mast cell stabilizers vs topical antihistamines (8 RCT) 
Levocabastine vs mast cell stabilisers OR 1.3[0.8;2.2] 
Confirm the benefit of 
topical mast cell 
stabilizers and 
antihistamines over 
placebo for the 
treatment of allergic 
conjunctivitis. There is 
insufficient 
evidence to recommend 












2184 eyes) Mean 















NSAID vs placebo 
(n=2) 









and  corneal 
involvement 
: 
Itching (mytomicin; sodium cromoglicate, ciclosporin 2%, 
ketorolac) SMD -1.43 [-1.76;-1.10] 
Tearing (mytomicin, sodium cromoglicate, cilosporin 2%) SMD 
-0.84[-1.20;-0.49] 
Photophobia (mytomicin, sodium cromoglicate, cyclosporine 
2%) -0.27[-0.82;0.39] 
Total signs (ciclosporin and sodium cromoglicate) SMD -0.94;[-
1.34;-0.54] 
Total symptoms (ciclosporin 2% and sodium cromoglicate) 
SMD -0.73[-1.14;-0.32] 
Tarsal papillae (mytomicin, sodium cromoglicate, ciclosporin) 
SMD -0.32[-0.64:-0.00] 
Corneal Involvement (mytomicin, sodium cromoglicate, 
ciclosporin) SMD -1.15[-1.50;-0.80] 
Limbal disease (mytomicin, sodium cromoglicate, ciclosporin) 
SMD -1.17[-1.50;-0.83] 
Hyperaemia (mytomicin, sodium cromoglicate, ciclosporin, 
mipragoside 0.5) SMD -1.07[-1.38;-0.76] 
 
The currently available 
topical drugs are 
effective in treating 
acute phases of VKC. 
There is a lack of 
evidence to support the 
recommendation of one 
specific type of 





RCT- randomized clinical trials; SMD= standardized mean difference; NSAID- non steroid anti-inflammatory drug; CCT-Corticosteroids * nedocromil sodium or sodium cromoglycate, olopatadine, ketotifen, 
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Outcomes Main results Author`s conclusion Amstar 
score 
Non-steroid anti-inflammatory drug 
Swamy et al, 
2007(15) 
8 RCT Allergic 
conjunctivitis 
(n=712) 








Symptoms, ocular itching and 
conjunctival injection 
Side effects 
Itching SMD -0.54[-0.84;-0.24] 
Lacrimation SMD -0.21[-0.41;-0.01] 
Conjunctival injection SMD -0.52[-0.97;-0.05] 
Ocular discomfort with treatment SMD 
3.97[2.67;5.89] 
NSAID are more 
effective than placebo in 
reducing conjunctival 
itching and improving a 
cardinal sign 
Low 
















Symptoms score change Decrease short term treatment in comparison 
with placebo (7-14 days) in 3 studies; 2 cross-over 
without benefit ketorolac 0.5%. Diclofenac 0.1% 
better than ketorolac 0.5% in 1 trial for  
symptoms. Data not pooled. 
Effective in decreasing 
short term symptoms 
Critically 
low 
Leukotriene antagonist (montelukast) 





Ocular eye disease 
12 SAC, 5 PAC 







Ocular symptom scores LTRA vs placebo (6 RCT) SMD -0.10[-0.14:-0.07] 
LTRA  vs oral anti-histamine (3RCT) 
0.08[0.02;0.14] in favor of antihistamines 
LTRA and oral antihistamine vs placebo (2RCT) -
0.30[-0.38;-0.21] 
In seasonal AC LTRAs 
are more efficacious 
than placebo but less 





AC- Alllergic conjunctivitis; CCT-Corticosteroids ; LTRA- Leukotriene receptor antagonists NSAID- non steroid anti-inflammatory drug;  PAC- Perennial allergic conjunctivitis; RCT- randomized clinical 
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Outcomes Main results Author`s conclusion Amstar 
score 
 





Rupatadine  vs 








Itchy and watery eyes Itch eyes SMD: - 0.29, 95% CI -0.45 to -0.14 
Watery eyes reduction SMD: -0.25, 95% CI -0.45 to 
-0.06 (;  
Improvement ocular 
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et al 2017 (84) 




Improvement of symptoms 
Elimination clinical signs 
Adverse effects  
No sufficient data on the improvement in 




safety and efficacy of 
topical treatments for 
BKC 
High 


















Incidence of IOP 0.2% suspension there was no increase in IOP for 
SAC or PAC; 0.5% suspension there was no 
increase in VKC or SAC (both in comparison with 
vehicle) 
Favorable IOP-safety 
profile for Llteprednol 
etabonate 
 with both short-term 
and long-term use 
Critically 
low 
















Ocular symptoms (ocular 
itching) Sign (bulbar 




Compared to placebo: 
Sign severity SMD -0.85[-1-35;-0.35] (all) 
SAC -0.45[-0.62;-0.28]; only one trial GPC and VKC 
Weighted mean difference -0.66[-0.97;-0.35] (all) 
SAC -0.43[-0.46;-0.31];  only one trial GPC and VKC 
IOP OR 3.03[1.04;8.80] 
 
Compared to topical olopatadine 
Sign severity SMD -3.78[-10.61;3.04] 
 
WMD -0.98[-2.00;0.05] (all interventions) 
 
Topical loteprednol 





Weiner J et al, 
1998(26) 











Ocular symptoms (included 
11 studies) 
Nasal steroid vs oral anti-histamines 
SMD -0.043[-0.157;0.072] 
There was no significant 
difference between 
intranasal 













Total ocular symptom score 
(TOSS) 
Data not pooled 
Improvement of TOSS in 9 out of 10 studies 
Total eye symptoms 5 out of 13 studies 
Intranasal 
corticosteroids have a 
positive impact on the 
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Fluticasone (7 RCT 
data association) 
Mometasone 









Total ocular symptom score  
 
Data not pooled, an improvement of total eye 
symptom score was seen versus placebo was seen 




well-tolerated in the 






Yánez A et al, 
2002(29) 



















Eye symptoms Nasal steroid vs nasal anti-histamines SMD -0.07[-
-0.27;0.12, p=0.4] 
There was no difference 
between interventions 





Wan KH et al, 
2013(32) 
7 RCT Allergic conjunctivitis 
(n=306 eyes of 153 







from 0.05% to 2% 
Composite sign score 
(average of at least one of the 
following signs: hyperemia, 
swelling, papillae and giant 
papillae 
on the tarsal conjunctiva, 
hyperemia and edema of the 
bulbar 
conjunctiva, or corneal 
involvement) 
Composite symptom score 
(average of: redness, 
tearing, burning, discomfort, 




Compared to placebo: 
Composite sign score: SMD -1.21 95%CI, [-1.80; -
0.62] 
Composite symptom score: SMD -0.84 95%CI[-
1.51;-0.16] 
Reduction on steroid eye drop (3RCT) SMD -61.2[-
101.6;-20.7] 
Topical cyclosporine 
could be an effective 
and safe treatment 
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González-
López et al, 
2012(33) 




or Cyclosporin 2% 
in maize oil vs 
preservative free 
artificial tears or 
placebo 
Symptoms improvement 
(reported by the participant) 
itching, tearing, discomfort, 
mucous discharge, 
photophobia or pain 




Symptoms composite score significantly improved 
for all associated, but not for specific symptoms in 
one study ( 
Clinical signs improved in the composite score in 
one study  
Reduction of topical steroid use in one study 
 
Topical CsA may 
provide clinical and 
symptomatic relief in 
AKC and may help to 
reduce topical steroid 
use in patients 
with steroid-dependent 
or steroid-resistant 
AKC. No serious adverse 
events were reported 
High 
























NSAID vs placebo 
(n=2= 




Irching, tearing, fotofobia, 
hyperemia, tarsal papillae, 
limbal disease and  corneal 
involvement 
Itching (mytomicin; sodium cromoglicate, 
ciclosporin 2%, ketorolac) SMD -1.43 [-1.76;-1.10] 
Tearing (mytomicin, sodium cromoglicate, 
cilosporin 2%) SMD -0.84[-1.20;-0.49] 
Photophobia (mytomicin, sodium cromoglicate, 
cyclosporine 2%) -0.27[-0.82;0.39] 
Total signs (ciclosporin and sodium cromoglicate) 
SMD -0.94;[-1.34;-0.54] 
Total symptoms (ciclosporin 2% and sodium 
cromoglicate) SMD -0.73[-1.14;-0.32] 
Tarsal papillae (mytomicin, sodium cromoglicate, 
ciclosporin) SMD -0.32[-0.64:-0.00] 
Corneal Involvement (mytomicin, sodium 
cromoglicate, ciclosporin) SMD -1.15[-1.50;-0.80] 
Limbal disease (mytomicin, sodium cromoglicate, 
ciclosporin) SMD -1.17[-1.50;-0.83] 
Hyperaemia (mytomicin, sodium cromoglicate, 
ciclosporin, mipragoside 0.5) SMD -1.07[-1.38;-
0.76] 
 
The currently available 
topical drugs are 
effective in treating 
acute phases of VKC. 
However, 
there is a lack of 
evidence to support the 
recommendation of one 
specific type of 
























Improvement of total score with tacrolimus versus 
placebo (-5.6 ±5.1 for tacrolimus 
ophthalmic suspension vs -0.1 ±4.5 for placebo) 
Similar effect to topical corticosteroids for AKC 
Needed more studies Critically 
low 
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Outcomes Main results Author`s conclusion Amstar 
score 
Immunotherapy 









or allergic rhinitis 
6,379 patients SCIT 
13,636 patients SLIT 
Weed,tree and 
grass pollens, 
molds, cat and dog 
dander, and house 
dust mites 
Difference symptom score 




 [SMD -0.53 (95% CI -0.63 to -0.42); SCIT -0.65(-
0.86 to -0.36) vs SLIT -0.48 (95%CCI -0.61 to -
0.36); 
Seasonal allergens (-0.37 (95% CI -0.45 to -0.28] 
Medication score 
SMD of -0.38 (95% CI -0.49, -0.26) [SCIT SMD -
0.52 (95% CI -0.75, -0.29) ; SLIT -0.31 (95% CI -
0.44, -0.18) 




in symptom, medication, 




Di Bona et al 
(47) 
2015 
13 RCT  Seasonal allergic 
rhinoconjuncitivitis 
(n=4659) 
Grass pollen SLIT 
versus placebo 
Phleum p5 or 5 
grass extracts 
Difference in symptom score 
Difference medication score 
Number adverse events 
Symptom  score (SMD, −0.28; 95%CI, −0.37 to 
−0.19; P < .001) 
Medication score (SMD, 
−0.24; 95%CI, −0.31 to −0.17; P < .001) 
OR adverse events 2.91 
Small benefit of grass 
SLIT tablets in the 
treatment of SARC 
Moderate 
Nelson et al, 
2015(48) 





Allergic rhinitis  
treated with IT 
(n=4016) and 
placebo (n=3743) 
SCIT vs SLIT grass 
pollen 
IT versus placebo 
SLIT tablets vs 
SLIT drops 
Difference in symptom score 
(rhinoconjuncitivitis score 
preferred) 
Difference medication score 
Symptom score [SCIT vs placebo SMDs (95% CI): -
0.32 (-0.45 to -0.18); SLIT vs placebo SMDs (95% 
CI): -0.32 (-0.41 to -0.23)] 
Medication score [SCIT vs placebo SMDs (95% CI): 
-0.33 (-0.52 to -0.13); SLIT vs Placebo SMDs (95% 
CI): -0.44 (-0.83 to -0.06)] 
No difference between SCIT or SLIT 
 
Comparable reduction 
in allergic conjunctivitis 
symptoms with SLIT 
and SCIT 
Moderate 















grass pollen SLIT 
tablet,  
Symptoms score  
Combined symptom-
medication score 
Relative clinical impact  
Reported post-treatment or 
season-long nasal  
Total symptom scores. 
100 × (score Placebo – score 
Active)/score Placebo) 
Five grass pollen SLIT tablets [ -0.30(-0.36, -
0.23)]; -29.6% (-23% to -37%) 
Timothy SLIT tablets -19.2% (-6% to -29%) 
Nasal corticosteroids [– 0.55 (-0.63, -0.47)] 
-23.5% (-7% to -54%) 
azelastine-fluticasone[SMD –1.00 (-1.10, -0.90)] 
-17.1% (-15% to -20%) 
H1-antihistamines [SMD -0.39 (-0.43, -0.35)] 
-15.0% (-3% to -26%) 
Montelukast [ –0.23 (-0.30, -0.16)] 
-6.5% (-3% to -10%) 
Grass pollen SLIT 
tablets had a greater 




montelukast and similar 
to the mean relative 
clinical impact of nasal 
corticosteroids 
Moderate 







Grass mix, dust 
mite, parietaria, 
timothy grass, 
olive, tree mix 
Symptom score No pooled  
All but two studies showed a greater improvement 
in SLIT 
Moderate strength in 










SLIT Grass, mites, 
weeds 
TOSS  
Individual symptom score 
TOSS (n=36 studies) SMD -0.41[-0.53;-0.28], not 
significant for perennial allergens (n=6) and  
SLIT is effective in 
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significant for children and adults 
Itch SMD -0.31[-0.42;-0.20] 
Watery eyes SMD -0.23[-0.34;-0.11] 
Red eyes SMD -0.33[-0.45;-0.22] 
No significant differences in medication score 
individual symptom 
score in subjects with 
ARC or conjunctivitis. 







AIT pollen and 
dust mite 
Percent difference in pre-to-
post change for conjunctivitis 
symptoms (<15% weak; 15-
40 moderate; > 40% strong) 
Without specific values of percent of increase for 
conjunctivitis.  
SCIT showed an improvement versus placebo in 
all studies and 4 out of 5 studies showed an 
improvement with SLIT. 
The strength 
of evidence is low for  
SCIT and moderate for 
SLIT in conjunctivitis 
symptoms improvement 
Moderate 










19 trials with 
seasonal allergen 
(grass pollen) 9 




Did not present specific data; not pooled Insufficient evidence 
that immunotherapy in 
any administration has 





IT- allergen mmunotherapy; DBRCT- Double blind randomized controlled trail; LNIT- nasal immunotherapy; OIT-oral immunotherapy; RCT- randomized clinical trials; SCIT- Subcutaneous 
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Table 7. Practical treatment of ocular allergy  
 
A. How to treat IgE-mediated 
diseases 
SAC and PAC 
Avoidance of clinically relevant allergens is the first step in the prevention of ocular allergy symptoms 
Topical antihistamines, mast cell stabilizers or double action drugs are the first choice of treatment, and all effective in reducing signs and 
symptoms 
Dual acting agents with combined mast cell stabilizer and antihistaminic function increase the possibility of symptom improvement, and 
have a faster relief of symptoms compared to mast cell stabilizers 
Avoid topical corticosteroids, as they are rarely needed 
Intranasal corticosteroids are effective and well-tolerated in the treatment of ocular symptoms associated with ARC, but should not be used 
if only ocular signs and symptoms are present 
Topical vasoconstrictors alleviate only hyperemia and should be used with caution for a short period of 5-7 days because of side effects and 
tachyphylaxis 
Systemic anti-histamines should be used in acute forms or when ocular symptoms are associated with other allergic co-morbidities 
Leukotriene inhibitors are reported to be less efficacious than oral antihistamines in adult SAC patients 
Consider SIT when specific sensitization is the main cause of ocular allergy, as it is effective for the treatment of ARC to seasonal allergens 
and perennial allergens 
SLIT has been shown to be effective in reducing total and individual ocular symptom score in subjects with conjunctivitis 
B. How to treat 
persistent/chronic forms (IgE- 
and non-IgE-mediated) VKC and 
AKC 
 
Avoidance of specific and non-specific triggers is the first step in the prevention of ocular allergy symptoms 
Use cold compresses, good eyelid hygiene, and lubricants 
Topical antihistamines, mast cell stabilizers or double action drugs are the first treatment choice and may be used in combination. They 
should be used frequently during the day and during the whole season 
Systemic anti-allergic drugs should be used when ocular symptoms are associated with other allergic co-morbidities 
Topical corticosteroids should be used as short, pulsed therapy, in acute exacerbations or when the cornea is involved, under 
ophthalmologist’s monitoring 
Topical calcineurin inhibitors, preferentially cyclosporine A (0.1% on-label treatment in the EU), may be used as a steroid-sparing agent in 
steroid-dependent patients followed in specialized centers; tacrolimus 0.1% eye drops should be reserved for severe VKC and AKC cases 
refractory to CsA (off-label treatment in the EU) 
A systemic immunosuppressive treatment should be prescribed in most refractory cases of AKC with visual threat. Cyclosporine is the most 
frequently used drug. Tacrolimus and mycophenolate mofetil are alternative options 
C. How to treat non IgE-
mediated diseases 
CBC 
Avoidance of irritants and/or sensitizing antigens 
Eyelid hygiene 
Emollients and skin moisturing agents 
Oral antihistamines can be used to alleviate eyelid itching and inflammation 














potency corticosteroids, such as hydrocortisone, desonide, and triamcinolone acetonide 
Topical calcineurin inhibitors skin ointments 0.03% or 0.1% have been shown to be useful in the treatment of lid eczema in AKC patients. 
Tolerability is a concern as burning sensation is frequently reported and secondary infections, although infrequent, have been recognized 
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